Number Of PET Scans Research Articles

Analysis of Smart Lung Tumour Detector and Stage Classifier Using Deep Learning Techniques with Internet of Things.

The use of artificial intelligence (AI) and the Internet of Things (IoT), which is a developing technology in medical applications that assists physicians in making more informed decisions regarding patients' courses of treatment, has become increasingly widespread in recent years in the field of healthcare. On the other hand, the number of PET scans that are being performed is rising, and radiologists are getting significantly overworked as a result. As a direct result of this, a novel approach that goes by the name “computer-aided diagnostics” is now being investigated as a potential method for reducing the tremendous workloads. A Smart Lung Tumor Detector and Stage Classifier (SLD-SC) is presented in this study as a hybrid technique for PET scans. This detector can identify the stage of a lung tumour. Following the development of the modified LSTM for the detection of lung tumours, the proposed SLD-SC went on to develop a Multilayer Convolutional Neural Network (M-CNN) for the classification of the various stages of lung cancer. This network was then modelled and validated utilising standard benchmark images. The suggested SLD-SC is now being evaluated on lung cancer pictures taken from patients with the disease. We observed that our recommended method gave good results when compared to other tactics that are currently being used in the literature. These findings were outstanding in terms of the performance metrics accuracy, recall, and precision that were assessed. As can be shown by the much better outcomes that were achieved with each of the test images that were used, our proposed method excels its rivals in a variety of respects. In addition to this, it achieves an average accuracy of 97 percent in the categorization of lung tumours, which is much higher than the accuracy achieved by the other approaches.

Plasma amyloid-\u03b2 oligomerization assay as a pre-screening test for amyloid status

ObjectiveWe assessed the performance of plasma amyloid oligomerization tendency (OAβ) as a marker for abnormal amyloid status. Additionally, we examined long-term storage effects on plasma OAβ.MethodsWe included 399 subjects regardless of clinical diagnosis from the Amsterdam Dementia Cohort and European Medical Information Framework for AD project (age, 63.8 ± 6.6; 44% female). Amyloid status was determined by visual read on positron emission tomography (PET; nabnormal = 206). Plasma OAβ was measured using the multimer detection system (MDS). Long-term storage effects on MDS-OAβ were assessed using general linear models. Associations between plasma MDS-OAβ and Aβ-PET status were assessed using logistic regression and receiver operating characteristics analyses. Correlations between plasma MDS-OAβ and CSF biomarker levels were evaluated using Pearson correlation analyses.ResultsMDS-OAβ was higher in individuals with abnormal amyloid, and it identified abnormal Aβ-PET with an area under the curve (AUC) of 0.74 (95% CI, 0.67–0.81), especially in samples with a storage duration < 4 years. Combining APOEe4 and age with plasma MDS-OAβ revealed an AUC of 81% for abnormal amyloid PET status (95% CI, 74–87%). Plasma MDS-OAβ correlated negatively with MMSE (r = − 0.29, p < .01) and CSF Aβ42 (r = − 0.20, p < 0.05) and positively with CSF Tau (r = 0.20, p = 0.01).ConclusionsPlasma MDS-OAβ combined with APOEe4 and age accurately identifies brain amyloidosis in a large Aβ-confirmed population. Using plasma MDS-OAβ as a screener reduced the costs and number of PET scans needed to screen for amyloidosis, which is relevant for clinical trials. Additionally, plasma MDS-OAβ levels appeared affected by long-term storage duration, which could be of interest for others measuring plasma Aβ biomarkers.

Dosimetry of [68Ga]-labeled compounds

This review compiles and analyzes the available dosimetry data of [68Ga] labeled compounds. Dosimetry data are given for [68Ga]DOTA-NOC, TOC, TATE, and NODAGA-RGDyK.The number of PET-scans with [68Ga]DOTA-compounds for imaging neuroendocrine tumors is increasing because [68Ga] has a higher affinity to somatostatin receptors (SSTR) in comparison to comparable [111In]-compounds. In addition, the better image resolution of the PET images provides improved diagnostics.Despite its widespread use literature on dosimetry of [68Ga]-labeled radiopharmaceuticals is sparse. In some cases the description of the underlying methodology is missing or human data are gained from the extrapolation of animal experiments. More and better documented dosimetry data will further promote the use of these promising new agents.

Influence of PET/CT-introduction on PET scanning frequency and indications

To evaluate the influence of the introduction of combined PET/CT scanners into clinical routine. This investigation addresses the quantitative changes between PET/CT and stand alone PET. The study included all examinations performed on stand alone PET- or PET/CT-scanners within 12 month prior to and after implementation of PET/CT. The final data analysis included five university hospitals and a total number of 15 497 exams. We distinguished exams on stand alone tomographs prior to and after installation of the combined device as well as PET/CT scans particularly with regard to disease entities. Various further parameters were investigated. The overall number of PET scans (PET and PET/CT) rose by 146% while the number of scans performed on stand alone scanners declined by 22%. Only one site registered an increase in stand alone PET. The number of exams for staging in oncology increased by 196% while that of cardiac scans decreased by 35% and the number of scans in neurology rose by 47%. The use of scans for radiotherapy planning increased to 7% of all PET/CT studies. The increase of procedures for so-called classic PET oncology indications was moderate compared to the more common tumors. An even greater increase was observed in some rare entities. The introduction of PET/CT led to more than a doubling of overall PET procedures with a main focus on oncology. Some of the observed changes in scanning frequency may be caused by a rising availability of new radiotracers and advancements of competing imaging methods. Nevertheless the evident increase in the use of PET/CT for the most common tumour types demonstrates its expanding role in cancer staging. The combination of molecular and morphologic imaging has not only found its place but is still gaining greater importance with new developments in technology and radiochemistry.

Utilization of positron emission tomography scans (PET) in the management of NSCLC at a center with limited access to this imaging modality

6140 Background: PET is recommended as an important diagnostic aid in the initial evaluation of patients with lung cancer, according to the NCCN guidelines. The aim of this study is to estimate the proportion of NSCLC patients receiving PET, its impact on staging, and its utilization by different treating specialties, in a facility with limited access to PET. This is a situation comparable to several community medical centers. This study was done at the Veterans Hospital, Little Rock (VALR), where the requested PET scans were done at an outside facility, due to its unavailability within this center. Methods: All patients with NSCLC who were diagnosed or treated at VALR between 01/01/03 and 06/30/05 were retrospectively identified from the tumor registry, and details of PET were obtained. Subsequently electronic patient records at VALR were reviewed and the best estimate of pre-PET and post-PET stage was made. The details of the requesting specialty were also obtained. Then frequency distributions relevant to the aims of the study were calculated. Results: 444 patients with diagnosis of NSCLC were identified in this time period, of which 48 (10.8%) had PET scans. Overall 10 (21%) patients were down staged and 4 (8.3%) patients were upstaged. PET helped establish stage among 13 of 15 patients with unknown stage. Details are provided in the table . The number of PET scans requested by treating specialties are as follows: medical oncology 44% (21), pulmonary 40% (19), cardiothoracic surgery 13% (6), and others 3% (2). Conclusions: In this study 10.8% of patients with NSCLC had PET. There was establishment of, or change in stage among 27 (56%) patients. These numbers are comparable to studies from larger centers with ready availability to PET, reflecting its adequate utilization in this setting with limited access. Medical oncology and pulmonary services initiated majority of the PET requests, possibly because of their involvement in the early diagnostic work-up in this patient population. [Table: see text] No significant financial relationships to disclose.

Clinical oncologic positron emission tomography: an introduction.

PET imaging is a molecular imaging technology that is diffusing into imaging departments quite rapidly. The unique characteristics of positron emitting radionuclides such as fluorine-18 provide high-quality images with reasonable acquisition times. The imaging instrumentation continues to improve with new detector materials and combinations of PET scanners and CT scanners. FDG is now readily available to most hospitals in the United States. Third-party payers now recognize the importance of PET imaging in multiple malignancies. The number of PET scans performed annually will continue to increase as the indications increase and the instrumentation is more available.

Analysis of single‐subject data sets with a low number of PET scans

Analysis of single‐subject data sets with a low number of PET scans

A single subject analysis with low number of PET scans

A single subject analysis with low number of PET scans